

Recombinant Proteins Market by Product (Growth Factors, Chemokines, Structural Proteins, Membrane Proteins), Application (Drug Discovery & Development (Biologics, Vaccines, Cell & Gene Therapy), Research, Biopharma Production) & Region - Global Forecast to 2028

Market Report | 2024-02-05 | 408 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The global recombinant proteins market size is projected to reach USD 3.2 billion by 2028 from USD 2.2 billion in 2023, at a CAGR of 7.2% during the forecast period. Factors such as rising demand for biologics & biosimilars due to patent expiry, increasing prevalence of chronic diseases, increased government support for life sciences research & development and growing preference for personalized medicine..

"The growth factors and chemokines segment segment held the dominant share in the recombinant proteins market"

Based on product, the global recombinant proteins market is segmented into growth factors and chemokines, kinase proteins, membrane proteins, immune response proteins, structural proteins, regulatory proteins, recombinant metabolic enzymes, adhesion molecules and receptors, and other recombinant proteins. The growth factors and chemokines segment is further segmented into interferons, interleukins and other growth factor & chemokines. The growth factors and chemokines segment is anticipated to grow at significant CAGR due to their application in cell culture, protein expression, and modulation of cellular responses.

"Drug discovery & development segment accounted for the largest share of the application segment in 2022."

Based on application, the recombinant proteins market is segmented into, drug discovery and development, biopharmaceutical production, research, diagnostics, and other applications. In 2022, the drug discovery and development segment accounted for the largest share of the recombinant proteins market. The segment held the largest share in the market due to application of recombinant proteins in developing biopharmaceuticals and understanding the functions of potential drug targets.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

"Asia Pacific region is likely to grow at a faster pace in the recombinant proteins market."

The recombinant proteins market region is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and the Africa. Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period. The growth of the region is majorly driven by increasing demand for protein based drugs, rising government funding for recombinant proteins production and development of biotechnology-based drugs.

The primary interviews conducted for this report can be categorized as follows:

-□By Respondent: Supply Side- 70%, and Demand Side - 30%

-□By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%

-□By Region: North America: 40%, Europe: 25%, Asia Pacific: 20%, Latin America: 10%, and the Middle East and Africa: 5%

List of Companies Profiled in the Report:

-□Bio-Techne (US)

-□Thermo Fisher Scientific Inc. (US)

-□Merck KGaA (Germany)

-□Abcam plc (UK)

-□Abnova Corporation (Taiwan)

-□Biolegend Inc (US)

-□Bio-Rad Laboratories Inc. (US)

-□BPS Bioscienc Inc (US)

-□Enzo Biochem, Inc. (US)

-□GenScript (China)

-□Miltenyi Biotec B.V. & Co. KG (Germany)

-□Proteintech Group, Inc. (US)

-□Sino Biological Inc. (China)

-□ACROBiosystems Group (US)

-□Aviva Systems Biology Corporation (US)

-□Sartorius CellGenix GmbH (Germany)

-□Icosagen (Estonia)

-□Neuromics (US)

-□ProSpec-Tany Technogene Ltd. (Israel)

-□ProteoGenix S.A.S (France)

-□RayBiotech Inc (US)

-□Laurus Bio (India)

-□Stemcell Technologies (Canada)

-□StressMarq Biosciences Inc. (Canada)

-□United States Biological (US)

Research Coverage:

This report provides a detailed picture of the recombinant proteins market. It aims at estimating the size and future growth potential of the market across different segments such as the product, application, end-user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall recombinant proteins market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

-□Analysis of key drivers (rising incidence of chronic diseases, unleashing innovation in biologics and biosimilars with patent expiry, increasing government support for R&D in life sciences, growing preference for personalized medicine), restraints (high production costs, stringent regulatory approval processes), opportunities (advancements in gene editing technologies, high growth potential of emerging markets, emergence of novel expression systems) and challenges (challenges associated with delivery systems) are influencing the growth of recombinant proteins market.

-□Product Development/Innovation: Detailed insights on newly launched products of the recombinant proteins market.

-□Market Development: Comprehensive information about lucrative markets - the report analyses the recombinant proteins market across varied regions.

-□Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the recombinant proteins market.

-□Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players include Bio-Techne (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Abcam plc (UK), Abnova Corporation (Taiwan), Biolegend Inc (US), Bio-Rad Laboratories Inc. (US), BPS Bioscienc Inc (US), Enzo Biochem Inc. (US) and GenScript (China).

Table of Contents:

1□INTRODUCTION□33

1.1□STUDY OBJECTIVES□33

1.2□MARKET DEFINITION□33

1.2.1□INCLUSIONS AND EXCLUSIONS□33

1.3□MARKET SCOPE□34

1.3.1□MARKETS COVERED□34

1.3.2□YEARS CONSIDERED□35

1.3.3□CURRENCY CONSIDERED□35

1.4□RESEARCH LIMITATIONS□35

1.5□STAKEHOLDERS□36

1.6□SUMMARY OF CHANGES□36

1.7□RECESSION IMPACT□37

2□RESEARCH METHODOLOGY□38

2.1□RESEARCH DATA□38

FIGURE 1□RESEARCH DESIGN□38

2.1.1□SECONDARY DATA□39

2.1.2□PRIMARY DATA□40

FIGURE 2□RECOMBINANT PROTEINS MARKET: BREAKDOWN OF PRIMARIES□40

2.2□MARKET SIZE ESTIMATION□41

FIGURE 3□MARKET SIZE ESTIMATION: SUPPLY SIDE ANALYSIS (2022)□41

FIGURE 4□MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022□42

FIGURE 5□ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE ANALYSIS (2022)□42

2.2.1□INSIGHTS FROM PRIMARIES□44

FIGURE 6□MARKET VALIDATION FROM PRIMARY EXPERTS□44

2.2.2□SEGMENT ASSESSMENT (BY PRODUCT, APPLICATION, HOST CELL, AND END USER)□44

FIGURE 7□MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH□44

2.3□GROWTH RATE ASSUMPTIONS□45

FIGURE 8□RECOMBINANT PROTEINS MARKET: CAGR PROJECTIONS (2023-2028)□46

FIGURE 9□RECOMBINANT PROTEINS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES□46

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2.4	MARKET BREAKDOWN AND DATA TRIANGULATION	47
FIGURE 10	DATA TRIANGULATION METHODOLOGY	47
2.5	STUDY ASSUMPTIONS	48
2.6	RISK ANALYSIS	48
2.7	RECESSION IMPACT ANALYSIS	48
TABLE 1	GLOBAL INFLATION RATE PROJECTIONS, 2024?2028 (% GROWTH)	49
TABLE 2	US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)	49
TABLE 3	US HEALTH EXPENDITURE, 2023-2027 (USD MILLION)	49
3	EXECUTIVE SUMMARY	50
FIGURE 11	RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)	50
FIGURE 12	RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)	51
FIGURE 13	RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2023 VS. 2028 (USD MILLION)	51
FIGURE 14	RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2023 VS. 2028 (USD MILLION)	52
FIGURE 15	RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2023 VS. 2028 (USD MILLION)	53
FIGURE 16	RECOMBINANT PROTEINS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)	54
FIGURE 17	GEOGRAPHICAL SNAPSHOT OF RECOMBINANT PROTEINS MARKET	55
4	PREMIUM INSIGHTS	56
4.1	RECOMBINANT PROTEINS MARKET OVERVIEW	56
FIGURE 18	INCREASING GOVERNMENT SUPPORT FOR R&D IN LIFE SCIENCES TO DRIVE MARKET	56
4.2	NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY PRODUCT (2022)	57
FIGURE 19	GROWTH FACTORS & CHEMOKINES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022	57
4.3	RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2023 VS. 2028	58
FIGURE 20	GROWTH FACTORS & CHEMOKINES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD	58
4.4	RECOMBINANT PROTEINS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	58
FIGURE 21	ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD	58
5	MARKET OVERVIEW	59
5.1	INTRODUCTION	59
5.2	MARKET DYNAMICS	59
FIGURE 22	RECOMBINANT PROTEINS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	59
TABLE 4	RECOMBINANT PROTEINS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	60
5.2.1	DRIVERS	60
5.2.1.1	Rising incidence of chronic diseases	60
FIGURE 23	NUMBER OF CANCER CASES IN US (2017 - 2022)	61
5.2.1.2	Increasing demand for biologics and biosimilars due to patent expiry	62
5.2.1.3	Increasing government support for R&D in life sciences	63
TABLE 5	GOVERNMENT FUNDING FOR LIFE SCIENCE RESEARCH (2022)	63
5.2.1.4	Growing preference for personalized medicine	64
5.2.2	RESTRAINTS	64
5.2.2.1	High production costs	64
5.2.2.2	Stringent regulatory approval processes	65
5.2.3	OPPORTUNITIES	66
5.2.3.1	Advancements in gene editing technologies	66
5.2.3.2	High growth potential of emerging markets	67
5.2.3.3	Emergence of novel expression systems	68
5.2.4	CHALLENGES	69
5.2.4.1	Challenges associated with delivery systems	69
5.3	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	69

FIGURE 24	REVENUE SHIFTS AND NEW REVENUE POCKETS FOR RECOMBINANT PROTEIN MANUFACTURERS	69
5.4	PRICING ANALYSIS	70
5.4.1	AVERAGE SELLING PRICE OF PRODUCTS, BY KEY PLAYERS	70
TABLE 6	RECOMBINANT PROTEIN PRODUCTS	70
5.4.2	AVERAGE SELLING PRICE TREND OF RECOMBINANT PROTEINS	74
5.5	TECHNOLOGY ANALYSIS	74
5.6	VALUE CHAIN ANALYSIS	75
FIGURE 25	VALUE CHAIN ANALYSIS: MANUFACTURING & ASSEMBLY PHASE CONTRIBUTES MAXIMUM VALUE TO VALUE CHAIN OF RECOMBINANT PROTEINS	76
5.7	ECOSYSTEM MARKET/MAP	77
FIGURE 26	ECOSYSTEM MARKET/MAP	77
TABLE 7	RECOMBINANT PROTEINS MARKET: ROLE IN ECOSYSTEM:	77
5.8	REGULATORY ANALYSIS	79
TABLE 8	KEY REGULATORY AGENCIES	79
5.8.1	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	81
TABLE 9	NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	81
TABLE 10	EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	82
TABLE 11	ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	83
TABLE 12	LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	83
TABLE 13	MIDDLE EAST: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	84
TABLE 14	AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	84
5.9	PORTER'S FIVE FORCES ANALYSIS	85
TABLE 15	RECOMBINANT PROTEINS MARKET: PORTER'S FIVE FORCES ANALYSIS	85
5.9.1	THREAT OF NEW ENTRANTS	85
5.9.2	THREAT OF SUBSTITUTES	85
5.9.3	BARGAINING POWER OF SUPPLIERS	86
5.9.4	BARGAINING POWER OF BUYERS	86
5.9.5	INTENSITY OF COMPETITIVE RIVALRY	86
5.10	PATENT ANALYSIS	87
FIGURE 27	PATENT APPLICATIONS FOR RECOMBINANT PROTEINS, DECEMBER 2013-DECEMBER 2023	87
TABLE 16	RECOMBINANT PROTEINS MARKET: INDICATIVE LIST OF PATENTS	87
5.11	KEY CONFERENCES AND EVENTS	89
TABLE 17	DETAILED LIST OF KEY CONFERENCES AND EVENTS (2023-2024)	89
5.12	KEY STAKEHOLDERS AND BUYING CRITERIA	90
5.12.1	KEY STAKEHOLDERS IN BUYING PROCESS	90
FIGURE 28	INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR RECOMBINANT PROTEINS	90
5.12.2	BUYING CRITERIA FOR RECOMBINANT PROTEINS	91
FIGURE 29	KEY BUYING CRITERIA FOR END USERS	91
6	RECOMBINANT PROTEINS MARKET, BY PRODUCT	92
6.1	INTRODUCTION	93
TABLE 18	RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	93
6.2	GROWTH FACTORS & CHEMOKINES	93
TABLE 19	RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY REGION, 2021-2028 (USD MILLION)	95
TABLE 20	RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021-2028 (USD MILLION)	95
TABLE 21	NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021-2028 (USD MILLION)	96
TABLE 22	EUROPE: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021-2028 (USD	

MILLION) 96

TABLE 23 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021-2028 (USD MILLION) 97

TABLE 24 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021-2028 (USD MILLION) 97

TABLE 25 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, COUNTRY, 2021-2028 (USD MILLION) 98

6.2.1 INTERFERONS (IFNS) 98

6.2.1.1 Ability to regulate critical cellular processes across research applications to propel market 98

TABLE 26 RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY REGION, 2021-2028 (USD MILLION) 99

TABLE 27 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY COUNTRY, 2021-2028 (USD MILLION) 100

TABLE 28 EUROPE: RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY COUNTRY, 2021-2028 (USD MILLION) 100

TABLE 29 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY COUNTRY, 2021-2028 (USD MILLION) 101

TABLE 30 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY COUNTRY, 2021-2028 (USD MILLION) 101

TABLE 31 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY COUNTRY, 2021-2028 (USD MILLION) 102

6.2.2 INTERLEUKINS (ILS) 102

6.2.2.1 Rising focus on personalized therapeutics to drive market 102

TABLE 32 RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY REGION, 2021-2028 (USD MILLION) 103

TABLE 33 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY COUNTRY, 2021-2028 (USD MILLION) 103

TABLE 34 EUROPE: RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY COUNTRY, 2021-2028 (USD MILLION) 104

TABLE 35 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY COUNTRY, 2021-2028 (USD MILLION) 104

TABLE 36 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY COUNTRY, 2021-2028 (USD MILLION) 105

TABLE 37 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY COUNTRY, 2021-2028 (USD MILLION) 105

6.2.3 OTHER GROWTH FACTORS & CHEMOKINES 105

TABLE 38 RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY REGION, 2021-2028 (USD MILLION) 106

TABLE 39 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021-2028 (USD MILLION) 106

TABLE 40 EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021-2028 (USD MILLION) 107

TABLE 41 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021-2028 (USD MILLION) 107

TABLE 42 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021-2028 (USD MILLION) 108

TABLE 43 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021-2028 (USD MILLION) 108

6.3 IMMUNE RESPONSE PROTEINS 109

6.3.1 HIGH UTILIZATION OF IMMUNE CHECKPOINT PROTEINS IN CANCER IMMUNOTHERAPY TO PROPEL MARKET 109

TABLE 44 RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY REGION, 2021-2028 (USD MILLION) 109

TABLE 45 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION) 110

TABLE 46 EUROPE: RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION) 110

TABLE 47 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION) 111

TABLE 48 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION) 111

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 49	MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)	112
6.4	STRUCTURAL PROTEINS	112
6.4.1	ATTACHMENT FACTORS IN CELL CULTURE APPLICATIONS TO DRIVE MARKET	112
TABLE 50	RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY REGION, 2021-2028 (USD MILLION)	113
TABLE 51	NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)	114
TABLE 52	EUROPE: RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)	114
TABLE 53	ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)	115
TABLE 54	LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)	115
TABLE 55	MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)	116
6.5	MEMBRANE PROTEINS	116
6.5.1	ESSENTIAL PROCESS REGULATION OF STRUCTURAL CELLS TO SUPPORT MARKET GROWTH	116
TABLE 56	RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY REGION, 2021-2028 (USD MILLION)	117
TABLE 57	NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)	117
TABLE 58	EUROPE: RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)	118
TABLE 59	ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)	118
TABLE 60	LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)	119
TABLE 61	MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)	119
6.6	KINASE PROTEINS	119
6.6.1	ACTIVE METABOLIZATION OF LIPIDS AND NUCLEOTIDES TO DRIVE MARKET	119
TABLE 62	RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY REGION, 2021-2028 (USD MILLION)	120
TABLE 63	NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)	120
TABLE 64	EUROPE: RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)	121
TABLE 65	ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)	121
TABLE 66	LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)	122
TABLE 67	MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)	122
6.7	REGULATORY PROTEINS	122
6.7.1	ABILITY TO MODULATE CELLULAR PROCESSES TO DRIVE MARKET	122
TABLE 68	RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS, BY REGION, 2021-2028 (USD MILLION)	123
TABLE 69	NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)	123
TABLE 70	RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS IN EUROPE, BY COUNTRY, 2021-2028 (USD MILLION)	124
TABLE 71	EUROPE: RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)	124
TABLE 72	LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)	125
TABLE 73	MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)	125
6.8	RECOMBINANT METABOLIC ENZYMES	126
6.8.1	HIGH ADOPTION IN BIOTECHNOLOGICAL APPLICATIONS FOR THERAPEUTIC DEVELOPMENT TO BOOST DEMAND	126
TABLE 74	RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY REGION, 2021-2028 (USD MILLION)	126

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 75	NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021-2028 (USD MILLION)	127
TABLE 76	EUROPE: RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021-2028 (USD MILLION)	127
TABLE 77	ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021-2028 (USD MILLION)	128
TABLE 78	LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021-2028 (USD MILLION)	128
TABLE 79	MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021-2028 (USD MILLION)	129
6.9	ADHESION MOLECULES & RECEPTORS	129
6.9.1	ENHANCED FACILITATION OF EXTRACELLULAR MATRIX INTERACTIONS TO SUPPORT MARKET GROWTH	129
TABLE 80	RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY REGION, 2021-2028 (USD MILLION)	130
TABLE 81	NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021-2028 (USD MILLION)	130
TABLE 82	EUROPE: RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021-2028 (USD MILLION)	131
TABLE 83	ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021-2028 (USD MILLION)	131
TABLE 84	LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021-2028 (USD MILLION)	132
TABLE 85	MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021-2028 (USD MILLION)	132
6.10	OTHER RECOMBINANT PROTEINS	132
TABLE 86	RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY REGION, 2021-2028 (USD MILLION)	133
TABLE 87	NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)	133
TABLE 88	EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)	134
TABLE 89	ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)	134
TABLE 90	LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)	135
TABLE 91	MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)	135
7	RECOMBINANT PROTEINS MARKET, BY APPLICATION	136
7.1	INTRODUCTION	137
TABLE 92	RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	137
7.2	DRUG DISCOVERY & DEVELOPMENT	137
TABLE 93	RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)	138
TABLE 94	RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2021-2028 (USD MILLION)	138
TABLE 95	NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)	139
TABLE 96	EUROPE: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)	139
TABLE 97	ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021-2028	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

(USD MILLION) 140

TABLE 98 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021-2028

(USD MILLION) 140

TABLE 99 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021-2028

(USD MILLION) 141

7.2.1 BIOLOGICS 141

7.2.1.1 High adoption in autoimmune disease & cancer treatment to propel market 141

TABLE 100 RECOMBINANT PROTEINS MARKET: KEY BIOLOGICS AND INDICATIONS 141

TABLE 101 RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY REGION, 2021-2028 (USD MILLION) 142

TABLE 102 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2021-2028 (USD MILLION) 142

TABLE 103 EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2021-2028 (USD MILLION) 143

TABLE 104 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2021-2028 (USD MILLION) 143

TABLE 105 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2021-2028 (USD MILLION) 144

TABLE 106 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2021-2028 (USD MILLION) 144

7.2.2 VACCINES 144

7.2.2.1 Rising incidence of infectious diseases to boost demand 144

TABLE 107 RECOMBINANT PROTEINS MARKET FOR VACCINES, BY REGION, 2021-2028 (USD MILLION) 145

TABLE 108 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION) 145

TABLE 109 EUROPE: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION) 146

TABLE 110 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION) 146

TABLE 111 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION) 147

TABLE 112 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION) 147

7.2.3 CELL & GENE THERAPY 147

7.2.3.1 Growing focus on CAR-T therapies to propel market 147

TABLE 113 RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY REGION, 2021-2028 (USD MILLION) 148

TABLE 114 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION) 149

TABLE 115 EUROPE: RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION) 149

TABLE 116 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION) 150

TABLE 117 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION) 150

TABLE 118 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION) 151

7.3 RESEARCH 151

TABLE 119 RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021-2028 (USD MILLION) 152

TABLE 120 RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY REGION, 2021-2028 USD MILLION) 152

TABLE 121 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION) 152

TABLE 122 EUROPE: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION) 153

TABLE 123 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION) 153

TABLE 124 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION) 154

TABLE 125 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION) 154

7.3.1 ACADEMIC RESEARCH 154

7.3.1.1 Wide application in molecular & gene expression studies to propel market 154

TABLE 126 RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH STUDIES, BY REGION, 2021-2028 (USD MILLION) 155

TABLE 127 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION) 155

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 128	EUROPE: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH STUDIES, BY COUNTRY, 2021-2028 (USD MILLION)	156
TABLE 129	ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)	156
TABLE 130	LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)	157
TABLE 131	MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)	157
7.3.2	BIOTECHNOLOGY RESEARCH	157
7.3.2.1	Growing focus on bioengineering and genomics to fuel market	157
TABLE 132	RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY REGION, 2021-2028 (USD MILLION)	158
TABLE 133	NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)	159
TABLE 134	EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)	159
TABLE 135	ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)	160
TABLE 136	LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)	160
TABLE 137	MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)	161
7.4	BIOPHARMACEUTICAL PRODUCTION	161
7.4.1	INCREASING DEVELOPMENT OF PROTEIN-BASED DRUGS TO SUPPORT MARKET GROWTH	161
TABLE 138	RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY REGION, 2021-2028 (USD MILLION)	162
TABLE 139	NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021-2028 (USD MILLION)	162
TABLE 140	EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021-2028 (USD MILLION)	163
TABLE 141	ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021-2028 (USD MILLION)	163
TABLE 142	LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021-2028 (USD MILLION)	164
TABLE 143	MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021-2028 (USD MILLION)	164
7.5	DIAGNOSTICS	164
7.5.1	GROWING FOCUS ON EARLY DISEASE DETECTION TO DRIVE MARKET	164
TABLE 144	RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY REGION, 2021-2028 (USD MILLION)	165
TABLE 145	NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021-2028 (USD MILLION)	165
TABLE 146	EUROPE: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021-2028 (USD MILLION)	166
TABLE 147	ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021-2028 (USD MILLION)	166
TABLE 148	LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021-2028 (USD MILLION)	167
TABLE 149	MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021-2028 (USD MILLION)	167
7.6	OTHER APPLICATIONS	167
TABLE 150	RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)	168
TABLE 151	NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)	168
TABLE 152	EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)	169

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 153	ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)	169
TABLE 154	LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)	170
TABLE 155	MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)	170
8	RECOMBINANT PROTEINS MARKET, BY HOST CELL	171
8.1	INTRODUCTION	172
TABLE 156	RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021-2028 (USD MILLION)	172
8.2	MAMMALIAN SYSTEMS	172
8.2.1	HIGH UPTAKE IN BIOTECHNOLOGY APPLICATIONS TO PROPEL MARKET	172
TABLE 157	RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY REGION, 2021-2028 (USD MILLION)	173
TABLE 158	NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021-2028 (USD MILLION)	173
TABLE 159	EUROPE: RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021-2028 (USD MILLION)	174
TABLE 160	ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021-2028 (USD MILLION)	174
TABLE 161	LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021-2028 (USD MILLION)	175
TABLE 162	MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021-2028 (USD MILLION)	175
8.3	INSECT CELLS	175
8.3.1	COST-EFFICIENT AND HIGH-YIELD CHARACTERISTICS TO DRIVE MARKET	175
TABLE 163	RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY REGION, 2021-2028 (USD MILLION)	176
TABLE 164	NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY COUNTRY, 2021-2028 (USD MILLION)	177
TABLE 165	EUROPE: RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY COUNTRY, 2021-2028 (USD MILLION)	177
TABLE 166	ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY COUNTRY, 2021-2028 (USD MILLION)	178
TABLE 167	LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY COUNTRY, 2021-2028 (USD MILLION)	178
TABLE 168	MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY COUNTRY, 2021-2028 (USD MILLION)	179
8.4	YEAST & FUNGI	179
8.4.1	NEW APPLICATIONS IN VACCINE DEVELOPMENT AND DIABETES TREATMENT TO BOOST DEMAND	179
TABLE 169	RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY REGION, 2021-2028 (USD MILLION)	180
TABLE 170	RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021-2028 (USD MILLION)	180
TABLE 171	RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021-2028 (USD MILLION)	181
TABLE 172	RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021-2028 (USD MILLION)	181
TABLE 173	LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021-2028 (USD MILLION)	182
TABLE 174	MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021-2028 (USD MILLION)	182
8.5	BACTERIAL CELLS	182
8.5.1	SIMPLIFIED GENETIC MANIPULATION AND SCALABILITY ADVANTAGES TO DRIVE MARKET	182
TABLE 175	RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY REGION, 2021-2028 (USD MILLION)	183
TABLE 176	RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021-2028 (USD MILLION)	184
TABLE 177	RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021-2028 (USD MILLION)	184
TABLE 178	ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021-2028 (USD MILLION)	185
TABLE 179	LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021-2028 (USD MILLION)	185
TABLE 180	MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021-2028 (USD MILLION)	185
8.6	OTHER HOST CELLS	186
TABLE 181	RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY REGION, 2021-2028 (USD MILLION)	186

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 182	NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021-2028 (USD MILLION)	187
TABLE 183	EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021-2028 (USD MILLION)	187
TABLE 184	ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021-2028 (USD MILLION)	188
TABLE 185	LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021-2028 (USD MILLION)	188
TABLE 186	MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021-2028 (USD MILLION)	189
9	RECOMBINANT PROTEINS MARKET, BY END USER	190
9.1	INTRODUCTION	191
TABLE 187	RECOMBINANT PROTEINS MARKET, BY END USER, 2021-2028 (USD MILLION)	191
9.2	PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES	191
9.2.1	RIISING DEVELOPMENT OF GENE THERAPIES AND VACCINES TO PROPEL MARKET	191
TABLE 188	RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2021-2028 (USD MILLION)	193
TABLE 189	NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)	193
TABLE 190	EUROPE: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)	194
TABLE 191	ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)	194
TABLE 192	LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)	195
TABLE 193	MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)	195
9.3	BIOTECHNOLOGY COMPANIES	195
9.3.1	RIISING NUMBER OF PROTEIN-BASED RESEARCH PROJECTS TO BOOST DEMAND	195
TABLE 194	RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2028 (USD MILLION)	196
TABLE 195	NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)	196
TABLE 196	EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)	197
TABLE 197	ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)	197
TABLE 198	LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)	198
TABLE 199	MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)	198
9.4	ACADEMIC & RESEARCH INSTITUTES	199
9.4.1	FAVORABLE GOVERNMENT INVESTMENTS TO PROPEL MARKET	199
TABLE 200	RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION)	200
TABLE 201	NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)	200
TABLE 202	EUROPE: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)	201
TABLE 203	ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)	201
TABLE 204	LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021-2028	

(USD MILLION) 202

TABLE 205 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021-2028

(USD MILLION) 202

9.5 CONTRACT RESEARCH ORGANIZATIONS 202

9.5.1 RISING OUTSOURCING OF CLINICAL TRIAL SERVICES TO SUPPORT MARKET GROWTH 202

TABLE 206 RECOMBINANT PROTEINS MARKET FOR CROS, BY REGION, 2021-2028 (USD MILLION) 203

TABLE 207 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR CROS, BY COUNTRY, 2021-2028 (USD MILLION) 203

TABLE 208 EUROPE: RECOMBINANT PROTEINS MARKET FOR CROS, BY COUNTRY, 2021-2028 (USD MILLION) 204

TABLE 209 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR CROS, BY COUNTRY, 2021-2028 (USD MILLION) 204

TABLE 210 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR CROS, BY COUNTRY, 2021-2028 (USD MILLION) 205

TABLE 211 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR CROS, BY COUNTRY, 2021-2028 (USD MILLION) 205

9.6 OTHER END USERS 205

TABLE 212 RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION) 206

TABLE 213 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION) 206

TABLE 214 EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION) 207

TABLE 215 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION) 207

TABLE 216 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION) 208

TABLE 217 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION) 208

Recombinant Proteins Market by Product (Growth Factors, Chemokines, Structural Proteins, Membrane Proteins), Application (Drug Discovery & Development (Biologics, Vaccines, Cell & Gene Therapy), Research, Biopharma Production) & Region - Global Forecast to 2028

Market Report | 2024-02-05 | 408 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*

Country*

Date

Signature